Association of Treatment Intensity and Adherence to Lipid-Lowering Therapy with Major Adverse Cardiovascular Events Among Post-MI Patients in Germany

被引:0
作者
Ingo Ahrens
Artak Khachatryan
Bondo Monga
Eugen Dornstauder
Eduard Sidelnikov
机构
[1] University of Cologne,Department of Cardiology and Medical Intensive Care, Augustinerinnen Hospital, Academic Teaching Hospital
[2] Certara,Faculty of Medicine and School of Public Health
[3] Evidence and Access (Previously-Analytica Laser),undefined
[4] Elsevier,undefined
[5] University of Lubumbashi,undefined
[6] Amgen GmbH,undefined
[7] Amgen (Europe) GmbH,undefined
来源
Advances in Therapy | 2021年 / 38卷
关键词
Cardiovascular disease; Lipid-lowering therapy; Myocardial infarction; Statins; Treatment adherence; Treatment intensity;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2532 / 2541
页数:9
相关论文
共 123 条
[1]  
Mach F(2020)2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Eur Heart J 41 111-188
[2]  
Baigent C(2016)Cardiovascular disease in Europe: epidemiological update 2016 Eur Heart J 37 3232-3245
[3]  
Catapano AL(2013)Prevalence of myocardial infarction and coronary heart disease in adults aged 40–79 years in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1) Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56 650-655
[4]  
Koskinas KC(2016)EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries Eur J Prev Cardiol 23 636-648
[5]  
Casula M(2016)2016 ESC/EAS guidelines for the management of dyslipidaemias Eur Heart J 37 2999-3058
[6]  
Badimon L(2016)2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR) Eur Heart J 37 2315-2381
[7]  
Townsend N(2018)Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and/or Ezetimibe JAMA Netw Open 1 e185554-1681
[8]  
Wilson L(2010)Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 1670-698
[9]  
Bhatnagar P(2014)Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review Br J Clin Pharmacol 78 684-186
[10]  
Wickramasinghe K(2007)Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction JAMA 297 177-790